Please assess the completion status of the following clinical trial:

Trial Title: MenPF-1 - A New Vaccine Against Meningococcal Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent for participation in the study~* Aged between 18 and 50 years~* In good health as determined by medical history, physical examination and clinical judgment of the investigators~* (Females) Willing to use effective contraception (such as the oral contraceptive pill, contraceptive implant or barrier methods) from one month prior and for the duration of the study~* Able to attend the scheduled visits and to comply with all study procedures, including internet access for the recording of diary cards~* Willing to allow his or her General Practitioner and/or Consultant, if appropriate, to be notified of participation in the study~* Confirmation from GP that they are aware of the inclusion and exclusion criteria and are satisfied from their knowledge of the volunteer that they are suitable to enrol~Exclusion Criteria:~* History of significant organ/system disease that could interfere with trial conduct or completion~* Have any known or suspected impairment or alteration of immune function~* Study significant abnormalities on screening investigations at the discretion of an Investigator~* Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination~* Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination~* Scheduled procedures requiring general anaesthesia during the study~* Participant who is terminally ill~* Receipt of immunoglobulin or any blood product transfusion within 3 months of study start~* Participation in another research study involving an investigational product in the past 12 weeks, or are planning to do so within the 20 weeks of this study~* Previously having received a meningococcal B vaccine of any kind~* Previous occurrence of disease caused by N. meningitidis~* Inability, in the opinion of the Investigator, to comply with all study requirements~* Female participants who are pregnant, lactating or planning pregnancy during the course of the study~* Any other significant disease or disorder which, in the opinion of the Investigator, may~  * Put the participants at risk because of participation in the study~ * Influence the result of the study~ * Impair the participant's ability to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Low dose vaccine arm (Type: EXPERIMENTAL): To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
- High dose vaccine arm (Type: EXPERIMENTAL): To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete